Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

CDK13 phosphorylates the translation machinery and promotes tumorigenic protein synthesis

Oncogene volume 42, pages 1321–1330 (2023)Cite this article

Subjects

Abstract

Cyclin-dependent kinase 13 (CDK13) has been suggested to phosphorylate RNA polymerase II and is involved in transcriptional activation. However, whether CDK13 catalyzes other protein substrates and how CDK13 contributes to tumorigenesis remain largely unclear. We here identify key translation machinery components, 4E-BP1 and eIF4B, as novel CDK13 substrates. CDK13 directly phosphorylates 4E-BP1 at Thr46 and eIF4B at Ser422; genetically or pharmacologically inhibiting CDK13 disrupts mRNA translation. Polysome profiling analysis shows that MYC oncoprotein synthesis strictly depends on CDK13-regulated translation in colorectal cancer (CRC), and CDK13 is required for CRC cell proliferation. As mTORC1 is implicated in 4E-BP1 and eIF4B phosphorylation, inactivation of CDK13 in combination with the mTORC1 inhibitor rapamycin further dephosphorylates 4E-BP1 and eIF4B and blocks protein synthesis. As a result, dual inhibition of CDK13 and mTORC1 induces more profound tumor cell death. These findings clarify the pro-tumorigenic role of CDK13 by direct phosphorylation of translation initiation factors and enhancing protein synthesis. Therefore, therapeutic targeting of CDK13 alone or in combination with rapamycin may pave a new way for cancer treatment.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: CDK13 interacts with the eIF4F complex in the cytoplasm.
Fig. 2: CDK13 directly phosphorylates 4EBP1 and eIF4B.
Fig. 3: CDK13 regulates protein synthesis.
Fig. 4: CDK13 regulates MYC mRNA translation and cancer cell proliferation.
Fig. 5: Synergistic targeting of CDK13 and mTORC1 in CRC cells and xenografts.

Similar content being viewed by others

Data availability

The accession number for the RNA-Seq data reported in this study have been submitted to the Gene Expression Omnibus under accession number GSE224287.

References

  1. Malumbres M. Cyclin-dependent kinases. Genome Biol. 2014;15:122.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Chou J, Quigley DA, Robinson TM, Feng FY, Ashworth A. Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy. Cancer Discov. 2020;10:351–70.

    Article  CAS  PubMed  Google Scholar 

  3. Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016;375:1738–48.

    Article  CAS  PubMed  Google Scholar 

  4. Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016;375:1925–36.

    Article  CAS  PubMed  Google Scholar 

  5. Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2017;35:2875–84.

    Article  CAS  PubMed  Google Scholar 

  6. Kumar SK, LaPlant B, Chng WJ, Zonder J, Callander N, Fonseca R, et al. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood. 2015;125:443–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Marqués F, Moreau JL, Peaucellier G, Lozano JC, Schatt P, Picard A, et al. A new subfamily of high molecular mass CDC2-related kinases with PITAI/VRE motifs. Biochem Biophys Res Commun. 2000;279:832–7.

    Article  PubMed  Google Scholar 

  8. Greenleaf AL. Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium. Transcription. 2019;10:91–110.

    Article  CAS  PubMed  Google Scholar 

  9. Fan Z, Devlin JR, Hogg SJ, Doyle MA, Harrison PF, Todorovski I, et al. CDK13 cooperates with CDK12 to control global RNA polymerase II processivity. Sci Adv. 2020;6:eaaz5041.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Bartkowiak B, Liu P, Phatnani HP, Fuda NJ, Cooper JJ, Price DH, et al. CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1. Genes Dev. 2010;24:2303–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Greifenberg AK, Hönig D, Pilarova K, Düster R, Bartholomeeusen K, Bösken CA, et al. Structural and Functional Analysis of the Cdk13/Cyclin K Complex. Cell Rep. 2016;14:320–31.

    Article  CAS  PubMed  Google Scholar 

  12. Liang K, Gao X, Gilmore JM, Florens L, Washburn MP, Smith E, et al. Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing. Mol Cell Biol. 2015;35:928–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Kim HE, Kim DG, Lee KJ, Son JG, Song MY, Park YM, et al. Frequent amplification of CENPF, GMNN and CDK13 genes in hepatocellular carcinomas. PloS ONE. 2012;7:e43223.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Wang J, Zhang Y, Lu L, Lu Y, Tang Q, Pu J. Insight into the molecular mechanism of LINC00152/miR-215/CDK13 axis in hepatocellular carcinoma progression. J Cell Biochem. 2019;120:18816–25.

    Article  CAS  PubMed  Google Scholar 

  15. Ramírez-Moya J, Miliotis C, Baker AR, Gregory RI, Slack FJ, Santisteban P. An ADAR1-dependent RNA editing event in the cyclin-dependent kinase CDK13 promotes thyroid cancer hallmarks. Mol Cancer. 2021;20:115.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Qi JC, Yang Z, Lin T, Ma L, Wang YX, Zhang Y, et al. CDK13 upregulation-induced formation of the positive feedback loop among circCDK13, miR-212-5p/miR-449a and E2F5 contributes to prostate carcinogenesis. J Exp Clin Cancer Res: CR. 2021;40:2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Lee LJ, Papadopoli D, Jewer M, Del Rincon S, Topisirovic I, Lawrence MG, et al. Cancer Plasticity: The Role of mRNA Translation. Trends Cancer. 2021;7:134–45.

    Article  CAS  PubMed  Google Scholar 

  18. Truitt ML, Ruggero D. New frontiers in translational control of the cancer genome. Nat Rev Cancer. 2016;16:288–304.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Merrick WC. eIF4F: a retrospective. J Biol Chem. 2015;290:24091–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell. 2009;136:731–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Parsyan A, Svitkin Y, Shahbazian D, Gkogkas C, Lasko P, Merrick WC, et al. mRNA helicases: the tacticians of translational control. Nat Rev Mol Cell Biol. 2011;12:235–45.

    Article  CAS  PubMed  Google Scholar 

  22. Böhm R, Imseng S, Jakob RP, Hall MN, Maier T, Hiller S. The dynamic mechanism of 4E-BP1 recognition and phosphorylation by mTORC1. Mol Cell. 2021;81:2403–16.e2405.

    Article  PubMed  Google Scholar 

  23. Raught B, Peiretti F, Gingras AC, Livingstone M, Shahbazian D, Mayeur GL, et al. Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases. EMBO J. 2004;23:1761–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Chen H, Liu H, Qing G. Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct Targeted Ther. 2018;3:5.

    Article  Google Scholar 

  25. Quereda V, Bayle S, Vena F, Frydman SM, Monastyrskyi A, Roush WR, et al. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer. Cancer Cell. 2019;36:545–58.e547.

    Article  CAS  PubMed  Google Scholar 

  26. Even Y, Durieux S, Escande ML, Lozano JC, Peaucellier G, Weil D, et al. CDC2L5, a Cdk-like kinase with RS domain, interacts with the ASF/SF2-associated protein p32 and affects splicing in vivo. J Cell Biochem. 2006;99:890–904.

    Article  CAS  PubMed  Google Scholar 

  27. Chen HH, Wong YH, Geneviere AM, Fann MJ. CDK13/CDC2L5 interacts with L-type cyclins and regulates alternative splicing. Biochem Biophys Res Commun. 2007;354:735–40.

    Article  CAS  PubMed  Google Scholar 

  28. Żuryń A, Krajewski A, Klimaszewska-Wiśniewska A, Grzanka A, Grzanka D. Expression of cyclin B1, D1 and K in non‑small cell lung cancer H1299 cells following treatment with sulforaphane. Oncol Rep. 2019;41:1313–23.

    PubMed  Google Scholar 

  29. Lu XL, Zhan R, Zhao GM, Qian ZH, Gong CC, Li YQ. Expression of CDK13 Was Associated with Prognosis and Expression of HIF-1α and beclin1 in Breast Cancer Patients. J Investig Surg. 2022;35:442–7.

    Article  Google Scholar 

  30. Duffy MJ, O’Grady S, Tang M, Crown J. MYC as a target for cancer treatment. Cancer Treatment Rev. 2021;94:102154.

    Article  CAS  Google Scholar 

  31. Choi SH, Martinez TF, Kim S, Donaldson C, Shokhirev MN, Saghatelian A, et al. CDK12 phosphorylates 4E-BP1 to enable mTORC1-dependent translation and mitotic genome stability. Genes Dev. 2019;33:418–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Schmidt S, Denk S, Wiegering A. Targeting Protein Synthesis in Colorectal Cancer. Cancers. 2020;12:1298.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov. 2011;10:868–80.

    Article  CAS  PubMed  Google Scholar 

  34. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proceed Natl Acad Sci USA. 2008;105:17414–9.

    Article  CAS  Google Scholar 

  35. Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, Dong J, et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res. 2004;10:1013–23.

    Article  CAS  PubMed  Google Scholar 

  36. Zhang Y, Zheng XF. mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. Cell Cycle. 2012;11:594–603.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Wang X, Beugnet A, Murakami M, Yamanaka S, Proud CG. Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins. Mol Cell Biol. 2005;25:2558–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Ito H, Ichiyanagi O, Naito S, Bilim VN, Tomita Y, Kato T, et al. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition. BMC Cancer. 2016;16:393.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Mi W, Ye Q, Liu S, She QB. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis. Oncotarget. 2015;6:13962–77.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Humphrey SJ, Karayel O, James DE, Mann M. High-throughput and high-sensitivity phosphoproteomics with the EasyPhos platform. Nat Protoc. 2018;13:1897–916.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank all members of the Liu lab for helpful suggestions, and the Core Facility of Medical Research Institute at Wuhan University for providing immunofluorescence and histology platforms. This study was supported by grants from National Key Research and Development Program of China (2022YFA1103200), National Natural Science Foundation of China (81970152, 82025003, 82161138024) and Hubei Provincial Natural Science Fund for Creative Research Groups (2021CFA003).

Author information

Author notes

  1. These authors contributed equally: Chao Wu, Ting Xie.

Authors and Affiliations

  1. Department of Hematology, Medical Research Institute, Zhongnan Hospital of Wuhan University, Wuhan University, 430071, Wuhan, China

    Chao Wu, Ting Xie & Hudan Liu

  2. Frontier Science Center of Immunology and Metabolism, Wuhan University, 430071, Wuhan, China

    Chao Wu, Ting Xie, Ying Guo, Donghai Wang, Ruyi Han, Guoliang Qing & Hudan Liu

  3. Department of Pathophysiology, School of Basic Medical Sciences, Wuhan University, 430071, Wuhan, China

    Min Qiu & Kaiwei Liang

Authors
  1. Chao Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ting Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ying Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Donghai Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Min Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ruyi Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Guoliang Qing
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kaiwei Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hudan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

HL conceived and designed the study. HL and GQ supervised the study. HL and CW wrote the paper. CW and TX performed most of the experiments. KL and MQ performed phosphorylation mass spectrometry analysis and provided HCT116 CDK13 AS cells. YG and RH assisted with cell-based assays. DW provided technical assistance for mouse experiments and valuable help in RNA-Seq and proteomics data analysis.

Corresponding author

Correspondence to Hudan Liu.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wu, C., Xie, T., Guo, Y. et al. CDK13 phosphorylates the translation machinery and promotes tumorigenic protein synthesis. Oncogene 42, 1321–1330 (2023). https://doi.org/10.1038/s41388-023-02653-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41388-023-02653-2

Search

Advanced search

Quick links